Cargando…

Mucolipidosis type III, a series of adult patients

BACKGROUND: Mucolipidosis type III α/β or γ (MLIII) are rare autosomal recessive diseases, in which reduced activity of the enzyme UDP-N-acetyl glucosamine-1-phosphotransferase (GlcNAc-PTase) leads to intra-lysosomal accumulation of different substrates. Publications on the natural history of MLIII,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oussoren, Esmee, van Eerd, David, Murphy, Elaine, Lachmann, Robin, van der Meijden, Jan C., Hoefsloot, Lies H., Verdijk, Rob, Ruijter, George J. G., Maas, Mario, Hollak, Carla E. M., Langendonk, Janneke G., van der Ploeg, Ans T., Langeveld, Mirjam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133174/ https://www.ncbi.nlm.nih.gov/pubmed/29704188 http://dx.doi.org/10.1007/s10545-018-0186-z

Ejemplares similares

Orofacial abnormalities in mucopolysaccharidosis and mucolipidosis type II and III: A systematic review
por: de Bode, Chiel J., et al.
Publicado: (2022)

Craniosynostosis affects the majority of mucopolysaccharidosis patients and can contribute to increased intracranial pressure
por: Oussoren, Esmee, et al.
Publicado: (2018)

Severe tracheal and bronchial collapse in adults with type II mucopolysaccharidosis
por: Rutten, M., et al.
Publicado: (2016)

Hip Morphology in Mucolipidosis Type II
por: Ammer, Luise Sophie, et al.
Publicado: (2020)

A Multiplex Assay for the Diagnosis of Mucopolysaccharidoses and Mucolipidoses
por: Langereis, Eveline J., et al.
Publicado: (2015)

Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease
por: Ernst, Martijn P.T., et al.
Publicado: (2020)

Registries for orphan drugs: generating evidence or marketing tools?
por: Hollak, Carla E. M., et al.
Publicado: (2020)

Developments in the treatment of Fabry disease
por: van der Veen, Sanne J., et al.
Publicado: (2020)

Using Out-of-Batch Reference Populations to Improve Untargeted Metabolomics for Screening Inborn Errors of Metabolism
por: Bongaerts, Michiel, et al.
Publicado: (2020)

Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy
por: van der Meijden, Jan C., et al.
Publicado: (2018)

Neurologic Abnormalities in Mouse Models of the Lysosomal Storage Disorders Mucolipidosis II and Mucolipidosis III γ
por: Idol, Rachel A., et al.
Publicado: (2014)

Association of Muscle Strength and Walking Performance in Adult Patients With Pompe Disease
por: Favejee, Marein M, et al.
Publicado: (2018)

Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients
por: van der Meijden, Jan C., et al.
Publicado: (2018)

Mucopolysaccharidosis: Cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI
por: Brands, Marion M. M. G., et al.
Publicado: (2012)

Correction: Neurologic Abnormalities in Mouse Models of the Lysosomal Storage Disorders Mucolipidosis II and Mucolipidosis III γ
Publicado: (2014)

Case Report: Mucolipidosis II and III Alpha/Beta Caused by Pathogenic Variants in the GNPTAB Gene (Mucolipidosis)
por: Mao, Shao-Jia, et al.
Publicado: (2022)

A Generic Assay to Detect Aberrant ARSB Splicing and mRNA Degradation for the Molecular Diagnosis of MPS VI
por: Broeders, Mike, et al.
Publicado: (2020)

Probing pathomechanisms of mucolipidosis II in fish
Publicado: (2012)

The Dictyostelium Model for Mucolipidosis Type IV
por: Allan, Claire Y., et al.
Publicado: (2022)

Social-cognitive functioning and social skills in patients with early treated phenylketonuria: a PKU-COBESO study
por: Jahja, Rianne, et al.
Publicado: (2016)

Long-Term Follow-Up of Cognition and Mental Health in Adult Phenylketonuria: A PKU-COBESO Study
por: Jahja, Rianne, et al.
Publicado: (2017)

Retrospective evaluation of the Dutch pre‐newborn screening cohort for propionic acidemia and isolated methylmalonic acidemia: What to aim, expect, and evaluate from newborn screening?
por: Haijes, Hanneke A., et al.
Publicado: (2019)

Autophagic dysfunction in mucolipidosis type IV patients
por: Vergarajauregui, Silvia, et al.
Publicado: (2008)

Correction to: Classical galactosemia: neuropsychological and psychosocial functioning beyond intellectual abilities
por: Welsink-Karssies, Mendy M., et al.
Publicado: (2020)

Classical galactosemia: neuropsychological and psychosocial functioning beyond intellectual abilities
por: Welsink-Karssies, Mendy M., et al.
Publicado: (2020)

An Additional Case of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine
por: Maas, Rutger J., et al.
Publicado: (2021)

Vacuolization of mucolipidosis type II mouse exocrine gland cells represents accumulation of autolysosomes
por: Boonen, Marielle, et al.
Publicado: (2011)

Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIB
por: Meijer, O. L. M., et al.
Publicado: (2016)

Antibodies against recombinant enzyme in the treatment of Fabry disease: Now you see them, now you don’t
por: van der Veen, Sanne Jolien, et al.
Publicado: (2022)

Mucolipidosis II: first report from Saudi Arabia
por: Alfadhel, Majid, et al.
Publicado: (2013)

Unique molecular signature in mucolipidosis type IV microglia
por: Cougnoux, Antony, et al.
Publicado: (2019)

Diagnosis of Mucopolysaccharidoses and Mucolipidosis by Assaying Multiplex Enzymes and Glycosaminoglycans
por: Arunkumar, Nivethitha, et al.
Publicado: (2021)

Lack of robust satellite cell activation and muscle regeneration during the progression of Pompe disease
por: Schaaf, Gerben J., et al.
Publicado: (2015)

Influence of sex and phenotype on cardiac outcomes in patients with Fabry disease
por: El Sayed, Mohamed, et al.
Publicado: (2021)

The first genetically confirmed Japanese patient with mucolipidosis type IV
por: Saijo, Harumi, et al.
Publicado: (2016)

Cross-sectional Observations on the Natural History of Mucolipidosis Type IV
por: Misko, Albert L., et al.
Publicado: (2022)

Secondary Hyperparathyroidism in Children with Mucolipidosis Type II (I-Cell Disease): Irish Experience
por: Boruah, Ritma, et al.
Publicado: (2022)

Position statement on the role of healthcare professionals, patient organizations and industry in European Reference Networks
por: Hollak, Carla E. M., et al.
Publicado: (2016)

Modeling cartilage pathology in mucopolysaccharidosis VI using iPSCs reveals early dysregulation of chondrogenic and metabolic gene expression
por: Broeders, M., et al.
Publicado: (2022)

The mucolipidosis IV Ca(2+) channel TRPML1 (MCOLN1) is regulated by the TOR kinase
por: Onyenwoke, Rob U., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1ra9nkk1e22137bvtombl2gnlu